News

Fintel reports that on June 28, 2024, Barclays initiated coverage of Charles River Laboratories International (NYSE:CRL) with a Equal-Weight recommendation.

Analyst Price Forecast Suggests 29.73% Upside

As of June 12, 2024, the average one-year price target for Charles River Laboratories International is 268.00. The forecasts range from a low of 228.26 to a high of $315.00. The average price target represents an increase of 29.73% from its latest reported closing price of 206.58.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Charles River Laboratories International is 4,596MM, an increase of 11.78%. The projected annual non-GAAP EPS is 13.24.

What is the Fund Sentiment?

There are 1,292 funds or institutions reporting positions in Charles River Laboratories International. This is an increase of 5 owner(s) or 0.39% in the last quarter. Average portfolio weight of all funds dedicated to CRL is 0.30%, an increase of 6.89%. Total shares owned by institutions decreased in the last three months by 0.92% to 58,499K shares.

The put/call ratio of CRL is 1.11, indicating a bearish outlook.

What are Other Shareholders Doing?

Kayne Anderson Rudnick Investment Management holds 1,878K shares representing 3.65% ownership of the company. In its prior filing, the firm reported owning 1,753K shares , representing an increase of 6.62%. The firm decreased its portfolio allocation in CRL by 20.63% over the last quarter.

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,614K shares representing 3.13% ownership of the company. In its prior filing, the firm reported owning 1,609K shares , representing an increase of 0.27%. The firm increased its portfolio allocation in CRL by 4.77% over the last quarter.

Clearbridge Investments holds 1,513K shares representing 2.94% ownership of the company. In its prior filing, the firm reported owning 1,468K shares , representing an increase of 2.98%. The firm increased its portfolio allocation in CRL by 8.36% over the last quarter.

Price T Rowe Associates holds 1,322K shares representing 2.57% ownership of the company. In its prior filing, the firm reported owning 1,443K shares , representing a decrease of 9.13%. The firm decreased its portfolio allocation in CRL by 4.19% over the last quarter.

NAESX - Vanguard Small-Cap Index Fund Investor Shares holds 1,310K shares representing 2.54% ownership of the company. In its prior filing, the firm reported owning 1,305K shares , representing an increase of 0.39%. The firm increased its portfolio allocation in CRL by 6.01% over the last quarter.

Charles River Laboratories International Background Information
(This description is provided by the company.)

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.